{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:30:04Z","timestamp":1761708604972},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T00:00:00Z","timestamp":1288915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T00:00:00Z","timestamp":1288915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>V<jats:sub>2<\/jats:sub>-receptor (V<jats:sub>2<\/jats:sub>R) stimulation potentially aggravates sepsis-induced vasodilation, fluid accumulation and microvascular thrombosis. Therefore, the present study was performed to determine the effects of a first-line therapy with the selective V<jats:sub>2<\/jats:sub>R-antagonist (Propionyl<jats:sub>1<\/jats:sub>-D-Tyr(Et)<jats:sub>2<\/jats:sub>-Val<jats:sub>4<\/jats:sub>-Abu<jats:sub>6<\/jats:sub>-Arg<jats:sub>8,9<\/jats:sub>)-Vasopressin on cardiopulmonary hemodynamics and organ function vs. the mixed V<jats:sub>1a<\/jats:sub>R\/V<jats:sub>2<\/jats:sub>R-agonist arginine vasopressin (AVP) or placebo in an established ovine model of septic shock.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>After the onset of septic shock, chronically instrumented sheep were randomly assigned to receive first-line treatment with the selective V<jats:sub>2<\/jats:sub>R-antagonist (1 \u03bcg\/kg per hour), AVP (0.05 \u03bcg\/kg per hour), or normal saline (placebo, each <jats:italic>n<\/jats:italic> = 7). In all groups, open-label norepinephrine was additionally titrated up to 1 \u03bcg\/kg per minute to maintain mean arterial pressure at 70 \u00b1 5 mmHg, if necessary.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Compared to AVP- and placebo-treated animals, the selective V<jats:sub>2<\/jats:sub>R-antagonist stabilized cardiopulmonary hemodynamics (mean arterial and pulmonary artery pressure, cardiac index) as effectively and increased intravascular volume as suggested by higher cardiac filling pressures. Furthermore, left ventricular stroke work index was higher in the V<jats:sub>2<\/jats:sub>R-antagonist group than in the AVP group. Notably, metabolic (pH, base excess, lactate concentrations), liver (transaminases, bilirubin) and renal (creatinine and blood urea nitrogen plasma levels, urinary output, creatinine clearance) dysfunctions were attenuated by the V<jats:sub>2<\/jats:sub>R-antagonist when compared with AVP and placebo. The onset of septic shock was associated with an increase in AVP plasma levels as compared to baseline in all groups. Whereas AVP plasma levels remained constant in the placebo group, infusion of AVP increased AVP plasma levels up to 149 \u00b1 21 pg\/mL. Notably, treatment with the selective V<jats:sub>2<\/jats:sub>R-antagonist led to a significant decrease of AVP plasma levels as compared to shock time (<jats:italic>P<\/jats:italic> &lt; 0.001) and to both other groups (<jats:italic>P<\/jats:italic> &lt; 0.05 vs. placebo; <jats:italic>P<\/jats:italic> &lt; 0.001 vs. AVP). Immunohistochemical analyses of lung tissue revealed higher hemeoxygenase-1 (vs. placebo) and lower 3-nitrotyrosine concentrations (vs. AVP) in the V<jats:sub>2<\/jats:sub>R-antagonist group. In addition, the selective V<jats:sub>2<\/jats:sub>R-antagonist slightly prolonged survival (14 \u00b1 1 hour) when compared to AVP (11 \u00b1 1 hour, <jats:italic>P<\/jats:italic> = 0.007) and placebo (11 \u00b1 1 hour, <jats:italic>P<\/jats:italic> = 0.025).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Selective V<jats:sub>2<\/jats:sub>R-antagonism may represent an innovative therapeutic approach to attenuate multiple organ dysfunction in early septic shock.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/cc9320","type":"journal-article","created":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T19:15:13Z","timestamp":1288984513000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental study"],"prefix":"10.1186","volume":"14","author":[{"given":"Sebastian","family":"Rehberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ertmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elbert","family":"Whorton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"D\u00fcnser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Katrin","family":"Strohh\u00e4cker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Lipke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim G","family":"Kampmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Van Aken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L","family":"Traber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,5]]},"reference":[{"key":"8810_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","volume":"36","author":"RP Dellinger","year":"2008","unstructured":"Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.\n                           Crit Care Med 2008, 36: 296-327. 10.1097\/01.CCM.0000298158.12101.41","journal-title":"Crit Care Med"},{"key":"8810_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"J Russell","year":"2008","unstructured":"Russell J, Walley K, Singer J, Gordon A, H\u00e9bert P, Cooper D, Holmes C, Mehta S, Granton J, Storms M, Cook D, Presneill J, Ayers D: Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock.\n                           N Engl J Med 2008, 358: 877-887. 10.1056\/NEJMoa067373","journal-title":"N Engl J Med"},{"key":"8810_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1742-7843.2006.pto_299.x","volume":"99","author":"MB Petersen","year":"2006","unstructured":"Petersen MB: The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease.\n                           Basic Clin Pharmacol Toxicol 2006, 99: 96-103. 10.1111\/j.1742-7843.2006.pto_299.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"8810_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/01.CCM.0000251127.45385.CD","volume":"35","author":"LK Barrett","year":"2007","unstructured":"Barrett LK, Singer M, Clapp LH: Vasopressin: mechanisms of action on the vasculature in health and in septic shock.\n                           Crit Care Med 2007, 35: 33-40. 10.1097\/01.CCM.0000251127.45385.CD","journal-title":"Crit Care Med"},{"key":"8810_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","volume":"1","author":"JE Kaufmann","year":"2003","unstructured":"Kaufmann JE, Vischer UM: Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).\n                           J Thromb Haemost 2003, 1: 682-689. 10.1046\/j.1538-7836.2003.00190.x","journal-title":"J Thromb Haemost"},{"key":"8810_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1056\/NEJM198804073181403","volume":"318","author":"DG Bichet","year":"1988","unstructured":"Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN: Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.\n                           N Engl J Med 1988, 318: 881-887. 10.1056\/NEJM198804073181403","journal-title":"N Engl J Med"},{"key":"8810_CR7","first-page":"H1888","volume":"263","author":"JF Liard","year":"1992","unstructured":"Liard JF: cAMP and extrarenal vasopressin V2 receptors in dogs.\n                           Am J Physiol 1992, 263: H1888-1891.","journal-title":"Am J Physiol"},{"key":"8810_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1046\/j.1538-7836.2003.00197.x","volume":"1","author":"JE Kaufmann","year":"2003","unstructured":"Kaufmann JE, Lezzi M, Vischer UM: Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling.\n                           J Thromb Haemost 2003, 1: 821-828. 10.1046\/j.1538-7836.2003.00197.x","journal-title":"J Thromb Haemost"},{"key":"8810_CR9","doi-asserted-by":"publisher","first-page":"P51","DOI":"10.1186\/cc6030","volume":"11","author":"DL Traber","year":"2007","unstructured":"Traber DL: Selective V1a receptor agonists in experimental septic shock [Abstract].\n                           Crit Care 2007, 11: P51. 10.1186\/cc6030","journal-title":"Crit Care"},{"key":"8810_CR10","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood.V86.7.2760.2760","volume":"86","author":"S Kanwar","year":"1995","unstructured":"Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P: Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules.\n                           Blood 1995, 86: 2760-2766.","journal-title":"Blood"},{"key":"8810_CR11","doi-asserted-by":"publisher","first-page":"P182","DOI":"10.1186\/cc7346","volume":"13","author":"S Rehberg","year":"2009","unstructured":"Rehberg S, Laporte R, Enkhbaatar P, La E, Wisniewski K, Traber LD, Rivi\u00e8re P, Traber DL: Arginine vasopressin increases plasma levels of von Willebrand factor in sheep.\n                           Crit Care 2009, 13: P182. 10.1186\/cc7346","journal-title":"Crit Care"},{"key":"8810_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1399-3011.1988.tb01376.x","volume":"32","author":"M Manning","year":"1988","unstructured":"Manning M, Klis WA, Kruszynski M, Przybylski JP, Olma A, Wo NC, Pelton GH, Sawyer WH: Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.\n                           Int J Pept Protein Res 1988, 32: 455-467. 10.1111\/j.1399-3011.1988.tb01376.x","journal-title":"Int J Pept Protein Res"},{"key":"8810_CR13","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1021\/jm00099a018","volume":"35","author":"M Manning","year":"1992","unstructured":"Manning M, Przybylski J, Grzonka Z, Nawrocka E, Lammek B, Misicka A, Cheng LL, Chan WY, Wo NC, Sawyer WH: Potent V2\/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.\n                           J Med Chem 1992, 35: 3895-3904. 10.1021\/jm00099a018","journal-title":"J Med Chem"},{"key":"8810_CR14","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1007\/s00134-009-1470-z","volume":"35","author":"S Rehberg","year":"2009","unstructured":"Rehberg S, Ertmer C, Kohler G, Spiegel HU, Morelli A, Lange M, Moll K, Schlack K, Van Aken H, Su F, Vincent JL, Westphal M: Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock.\n                           Intensive Care Med 2009, 35: 1286-1296. 10.1007\/s00134-009-1470-z","journal-title":"Intensive Care Med"},{"key":"8810_CR15","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1097\/01.CCM.0000287590.55294.40","volume":"35","author":"Z Wang","year":"2007","unstructured":"Wang Z, Su F, Rogiers P, Vincent JL: Beneficial effects of recombinant human activated protein C in a ewe model of septic shock.\n                           Crit Care Med 2007, 35: 2594-2600. 10.1097\/01.CCM.0000287590.55294.40","journal-title":"Crit Care Med"},{"key":"8810_CR16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/CCM.0b013e31816a1a0c","volume":"36","author":"M Westphal","year":"2008","unstructured":"Westphal M, Enkhbaatar P, Schmalstieg FC, Kulp GA, Traber LD, Morita N, Cox RA, Hawkins HK, Westphal-Varghese BB, Rudloff HE, Maybauer DM, Maybauer MO, Burke AS, Murakami K, Saunders F, Horvath EM, Szabo C, Traber DL: Neuronal nitric oxide synthase inhibition attenuates cardiopulmonary dysfunctions after combined burn and smoke inhalation injury in sheep.\n                           Crit Care Med 2008, 36: 1196-1204. 10.1097\/CCM.0b013e31816a1a0c","journal-title":"Crit Care Med"},{"key":"8810_CR17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1097\/01.CCM.0000215828.00289.B9","volume":"34","author":"M Westphal","year":"2006","unstructured":"Westphal M, Cox RA, Traber LD, Morita N, Enkhbaatar P, Schmalstieg FC, Hawkins HK, Maybauer DM, Maybauer MO, Murakami K, Burke AS, Westphal-Varghese BB, Rudloff HE, Salsbury JR, Jodoin JM, Lee S, Traber DL: Combined burn and smoke inhalation injury impairs ovine hypoxic pulmonary vasoconstriction.\n                           Crit Care Med 2006, 34: 1428-1436. 10.1097\/01.CCM.0000215828.00289.B9","journal-title":"Crit Care Med"},{"key":"8810_CR18","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/01.CIR.95.5.1122","volume":"95","author":"DW Landry","year":"1997","unstructured":"Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock.\n                           Circulation 1997, 95: 1122-1125.","journal-title":"Circulation"},{"key":"8810_CR19","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1097\/01.CCM.0000063046.82359.4A","volume":"31","author":"T Sharshar","year":"2003","unstructured":"Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D: Circulating vasopressin levels in septic shock.\n                           Crit Care Med 2003, 31: 1752-1758. 10.1097\/01.CCM.0000063046.82359.4A","journal-title":"Crit Care Med"},{"key":"8810_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00134-009-1595-0","volume":"35","author":"S Rehberg","year":"2009","unstructured":"Rehberg S, Ertmer C, Traber DL, Van Aken H, Westphal M: Selective V2-receptor-antagonism as a new therapeutic approach in ovine septic shock.\n                           Intensive Care Med 2009, 35: 111. #422 10.1007\/s00134-009-1595-0","journal-title":"Intensive Care Med"},{"key":"8810_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00134-009-1630-1","volume":"36","author":"C Torgersen","year":"2010","unstructured":"Torgersen C, D\u00fcnser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, Lorenz I, Schmid S, Westphal M, Grander W, Luckner G: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial.\n                           Intensive Care Med 2010, 36: 57-65. 10.1007\/s00134-009-1630-1","journal-title":"Intensive Care Med"},{"key":"8810_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0006-8993(91)91279-A","volume":"545","author":"R Landgraf","year":"1991","unstructured":"Landgraf R, Ramirez AD, Ramirez VD: The positive feedback action of vasopressin on its own release from rat septal tissue in vitro is receptor-mediated.\n                           Brain Res 1991, 545: 137-141. 10.1016\/0006-8993(91)91279-A","journal-title":"Brain Res"},{"key":"8810_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1164\/ajrccm.159.2.9802093","volume":"159","author":"A Pedoto","year":"1999","unstructured":"Pedoto A, Caruso JE, Nandi J, Oler A, Hoffmann SP, Tassiopoulos AK, McGraw DJ, Camporesi EM, Hakim TS: Acidosis stimulates nitric oxide production and lung damage in rats.\n                           Am J Respir Crit Care Med 1999, 159: 397-402.","journal-title":"Am J Respir Crit Care Med"},{"key":"8810_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0008-6363(98)00057-1","volume":"38","author":"G Simonis","year":"1998","unstructured":"Simonis G, Marquetant R, Rothele J, Strasser RH: The cardiac adrenergic system in ischaemia: differential role of acidosis and energy depletion.\n                           Cardiovasc Res 1998, 38: 646-654. 10.1016\/S0008-6363(98)00057-1","journal-title":"Cardiovasc Res"},{"key":"8810_CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1152\/jappl.1995.78.1.38","volume":"78","author":"AJ Ryan","year":"1995","unstructured":"Ryan AJ, Gisolfi CV: Responses of rat mesenteric arteries to norepinephrine during exposure to heat stress and acidosis.\n                           J Appl Physiol 1995, 78: 38-45.","journal-title":"J Appl Physiol"},{"key":"8810_CR26","first-page":"H482","volume":"258","author":"JF Liard","year":"1990","unstructured":"Liard JF: Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs.\n                           Am J Physiol 1990, 258: H482-489.","journal-title":"Am J Physiol"},{"key":"8810_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00005344-199503000-00006","volume":"25","author":"T Tagawa","year":"1995","unstructured":"Tagawa T, Imaizumi T, Shiramoto M, Endo T, Hironaga K, Takeshita A: V2 receptor-mediated vasodilation in healthy humans.\n                           J Cardiovasc Pharmacol 1995, 25: 387-392. 10.1097\/00005344-199503000-00006","journal-title":"J Cardiovasc Pharmacol"},{"key":"8810_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/01.ATV.0000191639.08082.04","volume":"26","author":"MG Rondaij","year":"2006","unstructured":"Rondaij MG, Bierings R, Kragt A, Gijzen KA, Sellink E, van Mourik JA, Fernandez-Borja M, Voorberg J: Dynein-dynactin complex mediates protein kinase A-dependent clustering of Weibel-Palade bodies in endothelial cells.\n                           Arterioscler Thromb Vasc Biol 2006, 26: 49-55. 10.1161\/01.ATV.0000191639.08082.04","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"8810_CR29","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1073\/pnas.0307446101","volume":"101","author":"R Radi","year":"2004","unstructured":"Radi R: Nitric oxide, oxidants, and protein tyrosine nitration.\n                           Proc Natl Acad Sci USA 2004, 101: 4003-4008. 10.1073\/pnas.0307446101","journal-title":"Proc Natl Acad Sci USA"},{"key":"8810_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1172\/JCI32730","volume":"118","author":"SW Chung","year":"2008","unstructured":"Chung SW, Liu X, Macias AA, Baron RM, Perrella MA: Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice.\n                           J Clin Invest 2008, 118: 239-247. 10.1172\/JCI32730","journal-title":"J Clin Invest"},{"key":"8810_CR31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/01.shk.0000248583.33270.12","volume":"27","author":"F Su","year":"2007","unstructured":"Su F, Wang Z, Cai Y, Rogiers P, Vincent JL: Fluid resuscitation in severe sepsis and septic shock: albumin, hydroxyethyl starch, gelatin or ringer's lactate-does it really make a difference?\n                           Shock 2007, 27: 520-526. 10.1097\/01.shk.0000248583.33270.12","journal-title":"Shock"},{"key":"8810_CR32","doi-asserted-by":"crossref","unstructured":"Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network\n                           N Engl J Med 2000, 342: 1301-1308. 10.1056\/NEJM200005043421801","DOI":"10.1056\/NEJM200005043421801"},{"key":"8810_CR33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1097\/01.CCM.0000063042.15272.84","volume":"31","author":"M Westphal","year":"2003","unstructured":"Westphal M, Stubbe H, Sielenkamper AW, Ball C, Van Aken H, Borgulya R, Bone HG: Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep.\n                           Crit Care Med 2003, 31: 1502-1508. 10.1097\/01.CCM.0000063042.15272.84","journal-title":"Crit Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc9320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cc9320\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc9320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:14:07Z","timestamp":1728303247000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc9320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,5]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,12]]}},"alternative-id":["8810"],"URL":"https:\/\/doi.org\/10.1186\/cc9320","relation":{},"ISSN":["1364-8535"],"issn-type":[{"type":"electronic","value":"1364-8535"}],"subject":[],"published":{"date-parts":[[2010,11,5]]},"assertion":[{"value":"30 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R200"}}